貝達藥業(300558.SZ)：上半年淨利升64.65%至1.44億元
格隆匯 8 月 5日丨貝達藥業(300558.SZ)披露2020年半年度報告，實現營業收入9.52億元，同比增長24.92%；歸屬於上市公司股東的淨利潤1.44億元，同比增長64.65%；歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.41億元，同比增長87.90%；基本每股收益0.36元。
2020 年上半年，新冠病毒疫情席捲全球，擾亂了正常的經濟運行節奏。國家統計局最新發布的數據顯示，隨着統籌推進疫情防控和經濟社會發展各項政策措施逐步落實落地，復工復產深入推進，生產經營秩序已穩步恢復，二季度增速實現由降轉升。
疫情下，公司緊跟國家步伐，牢牢保持戰略定力，始終秉承“Better Medicine, Better Life”的使命，堅持“成為總部在中國的跨國製藥企業”的發展願景，以“三駕馬車”戰略為引領，審時度勢，攻堅克難，報告期內實現埃克替尼銷售9.24億元，各項工作穩步推進。
報告期內，面對“4+7”帶量採購以及擴面執行，公司繼續實施埃克替尼“非凡TKI，我們不一樣”的差異化競爭策略，效果顯著。作為“非凡TKI”，埃克替尼療效確切、肝毒性低、安全性高，循證醫學臨牀證據豐富，中國人羣數據最全，在CSCO指南、衞健委診療規範及腦轉移人羣中獲優先推薦，且是目前唯一繼續開展贈藥項目的一代EGFR-TKI原研藥，患者負擔輕，能滿足患者長期用藥生存的需求。憑藉自身的獨特優勢，埃克替尼獲得了越來越多專家和患者的認可。
除了差異化競爭優勢外，產業環境變化也給埃克替尼的銷售帶來了機會。國家通過抗癌藥談判降價、加速納入醫保等一系列措施，提升了老百姓對“救命藥”的可及性，基層醫院的診療水平逐步提高，靶向藥逐步取代化療成為晚期肺癌患者的主要治療手段，埃克替尼被納入國家醫保目錄和國家基本藥物目錄。公司藉此機會推動渠道下沉，積極加強目標醫院的開發，努力提高醫院的覆蓋率，同時推進全國藥店醫保準入工作，保障了埃克替尼銷量的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
